Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When a genetic-testing company suddenly shifts from record COVID-19 volumes to building an oncology pipeline, its SEC paperwork gets complicated fast. Fulgent Genetics’ 300-page 10-K details everything from CLIA lab throughput to how Medicare reimbursement swings can squeeze margins, while each 8-K tracks acquisitions like CSI Labs that reshape the balance sheet overnight. Finding those nuggets manually is a time sink.
Stock Titan’s AI breaks down Fulgent Genetics SEC filings so you don’t have to. Receive real-time alerts the moment a Fulgent Genetics insider trading Form 4 transaction posts, skim concise highlights of every Fulgent Genetics quarterly earnings report 10-Q filing, and see complex revenue tables translated into plain English. Our platform covers the full spectrum—10-K annual reports, 10-Q quarterlies, 8-K material events, S-3 shelf registrations, and proxy statements outlining executive compensation—updated instantly from EDGAR.
- Spot founder Ming Hsieh’s executive stock transactions Form 4 in real time.
- Compare segment margins with side-by-side AI summaries across periods.
- Understand how new oncology drug spending flows through cash-flow statements.
Whether you’re asking, “How do I read Fulgent Genetics’ 10-K annual report?” or searching for the latest “Fulgent Genetics 8-K material events explained,” this page answers those questions. Our expert analysis plus AI-powered summaries turn dense disclosures into actionable insight—so you can focus on decisions, not document hunting.
Fulgent Genetics (FLGT) Q2-25 10-Q highlights
- Revenue: $81.8 m, up 15% YoY; 1H-25 revenue $155.3 m (+15%). Precision Diagnostics remains the largest line ($47.3 m, 58%).
- Gross margin: 42.1% vs 37.3% prior-year as cost discipline in laboratory services offsets mix shift.
- Operating loss: –$19.7 m (vs –$18.9 m). Operating expenses rose 19% to $54.1 m on higher G&A (+24%) and marketing spend (+43%).
- Net loss attributable to shareholders: –$19.0 m (EPS –$0.62) vs –$8.7 m (–$0.29). 1H-25 EPS –$0.99.
- Impairment: $9.9 m write-down of Helio Genomics investment drove other expense; without it, other income was $8.1 m interest.
- Cash & investments: $777 m (cash + marketable securities) with $87.9 m cash vs $55.1 m YE-24. Long-term securities declined $86 m as durations shortened; total assets $1.2 bn.
- Operating cash flow: –$34.6 m vs +$11.6 m prior year, due mainly to $33 m federal tax payments and higher receivables.
- Share activity: Repurchased $13.9 m stock YTD; share count 30.6 m.
- Customer concentration: One institutional customer accounted for 22% of Q2 revenue and 29% of receivables.
- Regulatory matters: DOJ CIDs on lab billing and HRSA audit remain open; SEC investigation closed with no action (previous $1 m accrual reversed).
Outlook: Management did not provide forward guidance in the filing. Revenue growth persists but profitability deteriorated due to higher opex and one-time impairment; cash position remains strong.
Fulgent Genetics (FLGT) filed a Form 4 showing that CFO & Treasurer Paul Kim had 2,743 common shares withheld on 07/26/2025 to cover taxes upon the vesting of RSUs tied to the 2022 Fulgent Pharma merger. The transaction was coded “F,” meaning it was an automatic, non-discretionary share surrender for tax withholding, not an open-market sale. The shares were valued at an implied $18.37 each (company-supplied price).
After the withholding, Kim directly owns 339,828 shares, so his economic exposure fell by <1 %. No derivative securities were exercised or disposed of, and no cash changed hands. Because the disposition is routine and immaterial relative to Kim’s total stake, the filing is largely neutral for investors and does not alter the company’s fundamental outlook.
Fulgent Genetics (FLGT) Form 4: Chief Scientific Officer Hanlin Gao satisfied tax-withholding liabilities from vested RSUs by allowing the company to withhold 1,642 common shares on 07/26/2025 at $18.37 each (transaction code F). Because the shares were retained by the issuer rather than sold on the open market, the transaction is administrative and does not signal active insider selling. Following the withholding, Gao’s direct holdings stand at 959,639 shares, a reduction of roughly 0.2%.
No derivative securities were exercised or disposed of, and no new shares were acquired. Given the small size relative to Gao’s total stake and FLGT’s public float, the filing has negligible impact on ownership structure or market supply.
Fulgent Genetics (FLGT) Form 4: Chief Scientific Officer Hanlin Gao satisfied tax-withholding liabilities from vested RSUs by allowing the company to withhold 1,642 common shares on 07/26/2025 at $18.37 each (transaction code F). Because the shares were retained by the issuer rather than sold on the open market, the transaction is administrative and does not signal active insider selling. Following the withholding, Gao’s direct holdings stand at 959,639 shares, a reduction of roughly 0.2%.
No derivative securities were exercised or disposed of, and no new shares were acquired. Given the small size relative to Gao’s total stake and FLGT’s public float, the filing has negligible impact on ownership structure or market supply.
PACCAR Inc. (PCAR) has submitted a Form 144 notifying the SEC of an intended insider disposition of 39,965 common shares via broker Charles Schwab & Co. The shares were obtained the same day, 29 Jul 2025, through an employee stock-option cashless exercise and carry an aggregate market value of roughly $3.98 million. With 524.96 million shares outstanding, the planned sale equals about 0.008 % of total shares.
No other sales were reported during the past three months, and the filer certifies the absence of undisclosed adverse information. Rule 144 filings serve only as advance notice; execution, timing, and pricing remain subject to market conditions and Rule 144 volume limits.
The modest size relative to PACCAR’s float suggests minimal direct impact on capitalization or liquidity, yet the filing may still be monitored by investors tracking insider sentiment.
On 07/25/2025, First Busey Corp. (BUSE) director Karen M. Jensen filed a Form 4 disclosing two transactions. She purchased 2,500 common shares in the open market at $23.25, committing roughly $58k. She also received 230 dividend-equivalent rights that converted into deferred stock units at no cost. After these trades, direct ownership rises to 83,798 shares.
No derivative activity was reported and Jensen’s role remains “Director” only. The open-market buy is typically viewed as a vote of confidence, yet the dollar amount is minor versus BUSE’s ±$1.3 bn market cap. Overall, the filing is a moderately positive sentiment signal but not a material event on its own.
FAQ
What is the current stock price of Fulgent Genetics (FLGT)?
What is the market cap of Fulgent Genetics (FLGT)?
What is the core business of Fulgent Genetics?
How does Fulgent Genetics generate its revenue?
What laboratory services does Fulgent Genetics offer?
How does the company integrate clinician partnerships into its business model?
What distinguishes Fulgent Genetics in the competitive genetic testing landscape?
What role does therapeutic development play at Fulgent Genetics?
